Evidence map›Paper›PMID 28097533›Full record

ReviewCurrent cardiology reports2017

Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.

Sara Ariotti, Giuseppe Gargiulo, Marco Valgimigli

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Sara AriottiDepartment of Cardiology, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland.
Giuseppe GargiuloDepartment of Cardiology, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland.
Marco ValgimigliDepartment of Cardiology, Bern University Hospital, University of Bern, CH-3010, Bern, Switzerland. marco.valgimigli@insel.ch.
University Hospital of Bern · CHUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis review aims to summarize and discuss safety and effectiveness of the long-term use of ticagrelor in patients with coronary artery disease (CAD). RECENT

findingsTicagrelor is an orally administered, direct, and reversible inhibitor of the P2Y

Indexed as

AdenosineBlood PlateletsCoronary Artery DiseaseHemorrhageHumansMyocardial InfarctionPurinergic P2Y Receptor AntagonistsRandomized Controlled Trials as TopicThrombosisTicagrelorTreatment OutcomeAdenosinePurinergic P2Y Receptor AntagonistsTicagrelorAntiplatelet therapyBleeding eventsCoronary artery diseaseIschemic eventsP2Y12 inhibitorTicagrelor

Identifiers

PMID28097533
OpenAlexW2578926377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.